AC Immune SA
ACIU
$2.95
-$0.01-0.17%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 423.10K | 1.58M | 1.10M | 1.10M | 1.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 423.10K | 1.58M | 1.10M | 1.10M | 1.29M |
| Cost of Revenue | 13.30M | 20.40M | 17.70M | 17.70M | 17.97M |
| Gross Profit | -12.87M | -18.81M | -16.60M | -16.60M | -16.68M |
| SG&A Expenses | 5.25M | 4.72M | 4.94M | 4.94M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -91.40K | -33.90K | 1.10K | 1.10K | -15.90K |
| Total Operating Expenses | 18.46M | 25.09M | 22.65M | 22.65M | 22.50M |
| Operating Income | -18.03M | -23.50M | -21.55M | -21.55M | -21.20M |
| Income Before Tax | -17.99M | -25.69M | -21.17M | -21.17M | -17.99M |
| Income Tax Expenses | -- | -- | -- | -- | 3.40K |
| Earnings from Continuing Operations | -17.99M | -25.69M | -21.17M | -21.17M | -17.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.99M | -25.69M | -21.17M | -21.17M | -17.99M |
| EBIT | -18.03M | -23.50M | -21.55M | -21.55M | -21.20M |
| EBITDA | -17.62M | -23.06M | -21.15M | -21.15M | -20.79M |
| EPS Basic | -0.18 | -0.26 | -0.21 | -0.21 | -0.18 |
| Normalized Basic EPS | -0.11 | -0.16 | -0.13 | -0.13 | -0.11 |
| EPS Diluted | -0.18 | -0.26 | -0.21 | -0.21 | -0.18 |
| Normalized Diluted EPS | -0.11 | -0.16 | -0.13 | -0.13 | -0.11 |
| Average Basic Shares Outstanding | 101.07M | 100.63M | 100.41M | 100.41M | 99.99M |
| Average Diluted Shares Outstanding | 101.07M | 100.63M | 100.41M | 100.41M | 99.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |